Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids

Diabetic Medicine

Volumn 26, Issue 5, 2009, Pages 532-539

  Brackenridge, A L ^a   Jackson, N ^b   Jefferson, W ^c   Stolinski, M ^b   Shojaee Moradie, F ^b   Hovorka, R ^d   Umpleby, A M ^b   Russell Jones, D ^a  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Intermediate density lipoprotein; Low density lipoprotein; Non esterified fatty acid; Peroxisome proliferators activated receptor agonist; Type 2 diabetes; Very low density lipoprotein

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN B100; FATTY ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS; MALE; MIDDLE AGED; PLACEBOS; STATISTICS, NONPARAMETRIC; THIAZOLIDINEDIONES;

EID: 65549145045     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02729.x     Document Type: Article

References (31)

1. Gale EA. Lessons from the glitazones: a story of drug development. Lancet 2001 357 : 1870 1875. (Pubitemid 32539124)
2. Yki-Jarvinen H. Thiazolidinediones. N Eng J Med 2004 351 : 1106 1118. (Pubitemid 39167514)
3. Nissen S, Wong K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Eng J Med 2007 356 : 2457 2471. (Pubitemid 46919772)
4. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. J Am Med Assoc 2000 283 : 1695 1702. (Pubitemid 30196209)
5. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001 86 : 280 288. (Pubitemid 32109807)
6. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001 24 : 308 315. (Pubitemid 32119130)
7. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000 23 : 1605 1611.
8. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001 111 : 10 17. (Pubitemid 32635256)
9. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002 56 : 251 257. (Pubitemid 34625022)
10. Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes, 2004 6 : 133 156. (Pubitemid 38220106)
11. Van Wijk JPH, Koning-Eelco JP, Martens EP, Ton J. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003 23 : 1744 1749. (Pubitemid 37254857)
12. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005 28 : 1547 1554. (Pubitemid 40923063)
13. Robinson AC, Jeffs JA, Gray RG, Bannister PA, Mather H, Gallagher JJ et al. Metabolic effects of troglitazone in patients with patients with diet-controlled type 2 diabetes. Eur J Clin Invest 2004 34 : 29 36. (Pubitemid 38221736)
14. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A et al. Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005 115 : 1323 1332. (Pubitemid 40629052)
15. Duez H, Lamarche B, Uffelman KD, Valéro R, Szeto L, Lemieux S et al. Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production. J Clin Endocrinol Metab 2008 93 : 1722 1729.
16. Beysen C, Murphy EJ, Nagaraja H, Decaris M, Riiff T, Fong A et al. A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipognesis in type 2 diabetes. J Lipid Res 2008 49 : 2657 2663.
17. Christ ER, Cummings MH, Albany E, Umpleby AM, Lumb PJ, Wierzbicki AS et al. Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein kinetics in patients with adult GH deficiency: a stable isotope study. J Clin Endocrinol Metab 1999 84 : 307 316. (Pubitemid 29036718)
18. Egusa GW, Brady D, Grundy SM, Howard BV. Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B. J Lipid Res 1983 24 : 1261 1267. (Pubitemid 14236576)
19. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modelling. Diabetes Care 2004 27 : 1487 1495.
20. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995 89 : 748 756.
21. Malmstrom R, Packard CJ, Caslake MJ, Bedford D, Stewart P, Yki-Järvinen H et al. Defective regulation of triglyceride metabolism by insulin in the liver in non insulin dependent diabetes. Diabetologia 1997 40 : 454 462. (Pubitemid 27132616)
22. Alam S, Stolinski M, Pentecost C, Boroujerdi MA, Jones RH, Sonksen PH et al. The effect of a six-month exercise program on very low density lipoprotein apolipoprotein B secretion in type 2 diabetes. J Clin Endocrinol Metabol 2004 89 : 688 694. (Pubitemid 38269878)
23. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med 2000 17 : 40 47. (Pubitemid 30094179)
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 : 7 22. (Pubitemid 34756487)
25. Adiels M, Boren J, Caslake MJ, Stewart P, Soro A, Westerbacka J et al. Overproduction of VLDL1 driven by hyperglycaemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005 25 : 1697 1703. (Pubitemid 41098943)
26. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003 46 : 733 749. (Pubitemid 36831401)
27. Lewis GF, Murdoch S, Uffelman K, Naples M, Szeto L, Albers A et al. Hepatic lipase mRNA, protein and plasma enzyme activity is increased in the insulin resistant, fructose-fed Syrian Golden Hamster and is partially normalized by the insulin sensitizer rosiglitazone. Diabetes 2004 53 : 2893 2900. (Pubitemid 39425915)
28. Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002 90 : 947 952. (Pubitemid 35232617)
29. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002 23 : 201 229. (Pubitemid 34299024)
30. Carpentier A, Taghibiglou C, Leung N, Szeto L, Van Iderstine SC, Uffelman KD et al. Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J Biol Chem 2002 277 : 28795 28802.
31. Watts GF, Barrett HR, Ji J, Serone AP, Chan DC, Croft KD et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003 52 : 803 811. (Pubitemid 36323589)